Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. - Wikidata - awgldk - TriplyDB

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

http://www.wikidata.org/entity/Q44769508

about

Alzheimer mechanisms and therapeutic strategies Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases Active and passive immunotherapy for neurodegenerative disorders Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Prion diseases: immunotargets and therapy Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Mechanism of Anti-α-Synuclein Immunotherapy Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation Disease-modifying therapeutic directions for Lewy-Body dementias Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target Tau-targeted treatment strategies in Alzheimer's disease Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging Immunotherapeutic approaches for Alzheimer's disease The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease Antibodies against alpha-synuclein reduce oligomerization in living cells Repression of alpha-synuclein expression and toxicity by microRNA-7.Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity Assessment of rat and mouse RGC apoptosis imaging in vivo with different scanning laser ophthalmoscopes Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Detecting morphologically distinct oligomeric forms of alpha-synuclein.Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian Models Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.

P2860

Q22252311-C4F4A725-41B9-4BE2-9411-71B2ACF6F75A Q24608911-922C6E2C-65A9-4B83-837C-30279AACE4A9 Q24650014-218AD61B-E539-4036-AEF4-C7C220E92784 Q24657879-7251DB95-7796-4651-8BC0-D743EC380259 Q26739412-D41AD21F-65AF-4853-9685-9D82991F53DA Q26741258-C00B4142-DC75-4DC3-8DF5-81D2C92048B9 Q26747508-C2BF092C-DCA1-47DF-8963-0DB0AF3ABC96 Q26772943-73F96AC5-8F52-4A30-8A1C-8DE9C62A9CF4 Q26781130-5F190765-C110-4068-8A80-219EED5279C2 Q26782907-9FF42977-14E2-4FF8-916C-CE7127ED5E23 Q26795984-A51872E1-25B5-4982-B7ED-457A317BC712 Q26853537-9A664732-6785-4E2C-BEB9-7027FBBC8AE4 Q27005843-BCA62616-9A9A-429B-A857-DC94C4283651 Q27015811-39BA881B-30FD-4FF8-97A9-3DB341DC7B91 Q27021159-09791ABC-55DB-4F93-9739-72C2BED61269 Q27023429-48B23812-0140-415E-A1FA-06EFAE5B822A Q27027973-10060B4B-9919-4B7A-99C9-FB723F3418B0 Q28067429-54C1D958-32F9-4FCE-ADF9-4992AA70B6EB Q28077869-64B0A2FC-992F-440F-B73A-7C5187F0804E Q28081278-3B9F9997-CA98-4C9B-84AB-1CE7352A3B68 Q28473538-57BDB6B4-9CEE-41B6-9453-B92C80F5B448 Q28740551-CE5964B6-B139-465C-BC91-A766E163E59B Q28743313-385D271E-A433-49A1-BCA2-49F54A0743A5 Q29542272-2A068B08-82B2-4BBE-AE6A-2C552EFEEAA4 Q30493249-3D7D6685-1DF3-416F-B249-01E0482170BF Q30578913-FF4CEB55-FEAA-448C-A2CE-F0C3214512BA Q30650119-4833AFAE-F6A3-437C-B98D-C0C04C88A6CC Q33280345-29BFDAE7-6B30-4AB6-9BC2-C5F335E134E2 Q33304015-2C531E36-9785-4739-8B09-3066620BA749 Q33307478-203D0AC5-BB53-40DA-A18F-792D99AD110B Q33312931-A1840D8A-3F04-4AAD-A76F-E0FE528EE81F Q33392127-CC829803-4FA3-41B1-99E3-5AD2BB6C99B6 Q33399653-D9CDACEB-68DE-4FFA-9A33-F5C33C8A6413 Q33526342-C05294F4-C140-40DF-831C-88B165062188 Q33613123-D06053B1-D9EB-49A8-84D9-28AB75B9605E Q33636374-6F02CCB0-5E2B-40E7-B202-2E3BDE4B6130 Q33670282-AFD688A5-B01E-42CD-9C46-4446FB5AC585 Q33701172-67C9D8FB-4ACA-46FE-A826-5DDF86D5493D Q33722313-2765FFCC-3EA4-4711-A550-256CCC14E1DA Q33726660-FDE0AD63-EE29-4E1E-AB50-E1977BA04B06

P2860

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

http://www.wikidata.org/entity/Q44769508

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@en

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@nl

type

label

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@en

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@nl

prefLabel

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@en

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@nl

P1433

Q44769508-EC6C94F3-AC25-4B6D-9854-FB268BDAF908

P1476

Q44769508-ACAA83E1-EB2F-42A5-B00B-FDA71900758D

P2093

Q44769508-3F312F81-1340-47E2-B5E3-E895AC93D23F

Q44769508-6886F56E-33AB-4676-9C33-D3871CD4019A

Q44769508-71F243AF-F8AC-450F-9659-DD405CD8DF4C

Q44769508-7A574B48-C656-4774-AE62-AD49D000C8A2

Q44769508-83A68CF0-3F50-4794-9C21-4394B51D8E64

Q44769508-92FBFF4E-26BD-46C7-ACF9-0F75B914F007

Q44769508-CF3F33B7-07D0-4A57-BC84-B16467A49A03

Q44769508-EFB91AE8-E8BC-43BD-814F-CDCEA4BE0071

Q44769508-F0A5C451-135C-4C95-9CC0-FC4773DC5065

P304

Q44769508-371EA6CF-F005-4A30-BE89-281B0C43176F

P31

Q44769508-4AF1F428-C6AF-48B6-A68D-EA826F5AC35F

P356

Q44769508-BE68610C-A5B2-4B1D-B5CB-F6B2BE30E412

P407

Q44769508-AC11564B-9808-4BCD-846E-9FB7C8C92F60

P433

Q44769508-2EF5FE97-AE27-4FF4-92ED-368FFAB36899

P478

Q44769508-160DFC16-ABB7-4213-BC2C-CB26A821252E

P50

Q44769508-02489540-53B3-4EE1-91A1-9A7CD0FE7B68

Q44769508-A7D38ADA-0D7E-470B-8F0B-081A7E2CFC7D

Q44769508-DF420B11-EF92-4582-838F-F056E8758CCC

P577

Q44769508-F7747F48-2825-414C-B1F5-4A61A7C51EE1

P5875

Q44769508-2868DDA2-BC57-4BE6-8ACF-8E43BA11BB1E

P698

Q44769508-B23C82BF-4E44-47EC-8404-B26B9EA7AFA4

P921

Q44769508-0A06DB3C-235D-4E11-9DC0-70B7E09705FF

Q44769508-23C72A6E-F4F7-4149-ACF8-03A621F65410

Q44769508-8FFA052B-07C3-4F02-BC12-2926F0691E10

P356

J.NEURON.2005.05.010

P1433

P1476

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

@en

P2093

Anthony Adame

http://www.w3.org/2001/XMLSchema#string

Dale Schenk

http://www.w3.org/2001/XMLSchema#string

Dora Games

http://www.w3.org/2001/XMLSchema#string

Jason Goldstein

http://www.w3.org/2001/XMLSchema#string

Makoto Hashimoto

http://www.w3.org/2001/XMLSchema#string

Michael Alford

http://www.w3.org/2001/XMLSchema#string

Michael Lee

http://www.w3.org/2001/XMLSchema#string

Peter Seubert

http://www.w3.org/2001/XMLSchema#string

Tamie Chilcote

http://www.w3.org/2001/XMLSchema#string

P304

857-868

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEURON.2005.05.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

Edward Rockenstein

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7790171

http://www.w3.org/2001/XMLSchema#string

P698

15953415

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease